BR0010373A - Uso de um agonista de cobre e método para identificação de um agonista de cobre - Google Patents
Uso de um agonista de cobre e método para identificação de um agonista de cobreInfo
- Publication number
- BR0010373A BR0010373A BR0010373-0A BR0010373A BR0010373A BR 0010373 A BR0010373 A BR 0010373A BR 0010373 A BR0010373 A BR 0010373A BR 0010373 A BR0010373 A BR 0010373A
- Authority
- BR
- Brazil
- Prior art keywords
- copper
- identifying
- agonists
- copper agonist
- agonist
- Prior art date
Links
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 title abstract 7
- 229910052802 copper Inorganic materials 0.000 title abstract 7
- 239000010949 copper Substances 0.000 title abstract 7
- 239000000556 agonist Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"USO DE UM AGONISTA DE COBRE E MéTODO PARA IDENTIFICAçãO DE UM AGONISTA DE COBRE". A invenção refere-se a um agonista do cobre que se liga ao sítio de ligação de cobre na APP e/ou exerce um efeito inibidor na liberação do peptídeo Ab amilóide participante no surgimento de doença de Alzheimer. A invenção também se refere a drogas contendo dito agonista de cobre ou à utilização de dito agonista do cobre para o preparo de uma droga para a detecção e/ou o tratamento da doença de Alzheimer. A invenção refere-se adicionalmente, ao método para identificação de agonistas de cobre tendo o efeito desejado descrito na invenção.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19909357A DE19909357A1 (de) | 1999-03-03 | 1999-03-03 | Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt |
| PCT/DE2000/000693 WO2000051632A2 (de) | 1999-03-03 | 2000-03-01 | Kupferagonist, der an die amyloid precursorprotein (app) bindet und/oder eine hemmende wirkung auf die amyloid-a beta-peptids ausübt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0010373A true BR0010373A (pt) | 2002-05-21 |
Family
ID=7899589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0010373-0A BR0010373A (pt) | 1999-03-03 | 2000-03-01 | Uso de um agonista de cobre e método para identificação de um agonista de cobre |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050186287A1 (pt) |
| EP (1) | EP1156811B1 (pt) |
| JP (1) | JP2002538168A (pt) |
| CN (1) | CN1263465C (pt) |
| AT (1) | ATE314079T1 (pt) |
| AU (1) | AU768715B2 (pt) |
| BR (1) | BR0010373A (pt) |
| CA (1) | CA2371934A1 (pt) |
| DE (2) | DE19909357A1 (pt) |
| RU (1) | RU2236235C2 (pt) |
| WO (1) | WO2000051632A2 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696263B1 (en) | 1999-09-23 | 2004-02-24 | Rigel Pharmaceuticals, Inc. | PCNA associated cell cycle proteins, compositions and methods of use |
| EP1242824A2 (en) * | 1999-12-30 | 2002-09-25 | 7TM Pharma | Screening using biological target molecules with metal-ion binding sites |
| AUPR202400A0 (en) * | 2000-12-12 | 2001-01-11 | Beyreuther, Konrad | Method of screening for inhibitors of alzheimer's disease |
| AU2009319864A1 (en) | 2008-11-25 | 2011-07-14 | Biogen Idec Ma Inc. | Use of DR6 and P75 antagonists to promote survival of cells of the nervous system |
| WO2012015050A1 (ja) * | 2010-07-29 | 2012-02-02 | 独立行政法人理化学研究所 | アミロイドβペプチド蓄積を伴う疾患の診断の為の可溶型アミロイドβ前駆体タンパク質770β切断産物の検出方法 |
| CN104122400B (zh) * | 2014-07-01 | 2016-03-02 | 上海依科赛生物制品有限公司 | 一种人体β淀粉样蛋白检测试剂盒及其用途 |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3277211B2 (ja) * | 1991-11-12 | 2002-04-22 | プラナ・バイオテクノロジー・リミテッド | アルツハイマー病の試験方法と治療方法 |
| CA2086165A1 (en) * | 1992-04-09 | 1993-10-10 | Paul P. Tamburini | Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein |
| AUPN649395A0 (en) * | 1995-11-10 | 1995-12-07 | Ramsay Health Care Pty Ltd | A method for diagnosing alzheimer's disease |
| JP2001514661A (ja) * | 1997-03-11 | 2001-09-11 | ザ ジェネラル ホスピタル コーポレイション | アルツハイマー病の処置における使用のための薬剤の同定 |
| DE19725619A1 (de) * | 1997-06-17 | 1998-12-24 | Fraunhofer Ges Forschung | Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien |
| CN100429230C (zh) * | 1997-10-24 | 2008-10-29 | 阿文蒂斯药物股份有限公司 | 能抑制早老素和β-淀粉样肽或其前体间相互作用的肽 |
| US6323218B1 (en) * | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
| AU1618000A (en) * | 1998-11-12 | 2000-05-29 | Du Pont Pharmaceuticals Company | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
-
1999
- 1999-03-03 DE DE19909357A patent/DE19909357A1/de not_active Withdrawn
-
2000
- 2000-03-01 WO PCT/DE2000/000693 patent/WO2000051632A2/de not_active Ceased
- 2000-03-01 CN CNB008067325A patent/CN1263465C/zh not_active Expired - Fee Related
- 2000-03-01 RU RU2001126346/15A patent/RU2236235C2/ru not_active IP Right Cessation
- 2000-03-01 DE DE50011974T patent/DE50011974D1/de not_active Expired - Fee Related
- 2000-03-01 AU AU40991/00A patent/AU768715B2/en not_active Ceased
- 2000-03-01 EP EP00920372A patent/EP1156811B1/de not_active Expired - Lifetime
- 2000-03-01 JP JP2000602298A patent/JP2002538168A/ja not_active Withdrawn
- 2000-03-01 CA CA002371934A patent/CA2371934A1/en not_active Abandoned
- 2000-03-01 AT AT00920372T patent/ATE314079T1/de not_active IP Right Cessation
- 2000-03-01 BR BR0010373-0A patent/BR0010373A/pt not_active IP Right Cessation
-
2004
- 2004-05-19 US US10/848,016 patent/US20050186287A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2236235C2 (ru) | 2004-09-20 |
| WO2000051632A2 (de) | 2000-09-08 |
| AU768715B2 (en) | 2004-01-08 |
| CN1263465C (zh) | 2006-07-12 |
| EP1156811B1 (de) | 2005-12-28 |
| WO2000051632A3 (de) | 2001-10-04 |
| DE50011974D1 (de) | 2006-02-02 |
| CN1352562A (zh) | 2002-06-05 |
| EP1156811A2 (de) | 2001-11-28 |
| DE19909357A1 (de) | 2000-09-07 |
| US20050186287A1 (en) | 2005-08-25 |
| CA2371934A1 (en) | 2000-09-08 |
| AU4099100A (en) | 2000-09-21 |
| JP2002538168A (ja) | 2002-11-12 |
| ATE314079T1 (de) | 2006-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN01053A1 (fr) | Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique | |
| BR0115427A (pt) | Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, e para prevenir a doença e o progresso da doença de alzheimer, e, uso de um composto | |
| ATE301994T1 (de) | Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda- antagonist | |
| ATE414519T1 (de) | Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit | |
| BR9910180A (pt) | Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico | |
| BRPI0407993A (pt) | inibidores de p38 e métodos para uso dos mesmos | |
| ECSP045520A (es) | Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos | |
| TW200510349A (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
| BR9709915A (pt) | Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto | |
| BR0213358A (pt) | Uso de flibanserina | |
| PT1011632E (pt) | Composicao farmaceutica para o tratamento de dismenorreia e parto prematuro | |
| PT942740E (pt) | Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf | |
| EP1274444A4 (en) | COMPOUNDS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS OR DISORDERS CAUSED BY THE ABUSE OF PSYCHOACTIVE SUBSTANCES | |
| ES2178157T3 (es) | Tratamiento de arritmias mediante la inhibicion de una proteina quinasa multifuncional dependiente de calcio/calmodulina. | |
| UY27993A1 (es) | Derivados de 4-pirrolidino-fenil-bencil eter | |
| BR9908510A (pt) | Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
| BR0010337A (pt) | Uso de ligantes receptores de dopamina d3 | |
| BR0010373A (pt) | Uso de um agonista de cobre e método para identificação de um agonista de cobre | |
| YU13301A (sh) | Muskarinski agonisti i antagonisti | |
| EP1003494A4 (en) | (d) -METHADONE, NON-OPIOID ANALGESIC | |
| BR0110506A (pt) | Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose | |
| BR0210650A (pt) | Tablete, e, uso do mesmo | |
| MXPA06002722A (es) | Composicion farmaceutica que comprende un antagonista del receptor p2x7 y un farmaco anti-inflamatorio no esteroidal. | |
| DK0946157T3 (da) | Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte | |
| BR0115424A (pt) | Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008. |